Table 3 Treatment and outcomes of patients with ILD and a positive anti-Ro52 antibody, stratified by ICU vs non-ICU (e.g. hospital or clinic) presentation at the time of anti-Ro52 lab testing. Pharmacotherapy includes all medications given, including in combination. Antifibrotic therapy includes medications approved for the treatment of idiopathic pulmonary fibrosis, including pirfenidone or nintedanib. Mortality is all-cause
From: Presentations and outcomes of interstitial lung disease and the anti-Ro52 autoantibody
Variable | All patients n = 73 | ICU presentation n = 13 | Non-ICU presentation n = 60 |
|---|---|---|---|
Age, years median [range] | 68 [23–90] | 60 [43–86] | 69 [23–90] |
Male, n (%) | 45 (61.6%) | 10 (76.9%) | 35 (58.3%) |
Ethnicity, n (%) | |||
African American | 7 (9.6%) | 2 (15.4%) | 5 (8.3%) |
Asian | 6 (8.2%) | 2 (15.4%) | 4 (6.7%) |
Hispanic | 4 (5.5%) | 0 (0%) | 4 (6.7%) |
White | 56 (76.7%) | 9 (69.2%) | 47 (78.3%) |
Smoking history, n (%) | |||
Current/Former | 43 (58.9%) | 10 (76.9%) | 33 (55%) |
Never | 30 (41.1%) | 3 (23.1%) | 27 (45%) |
Pharmacotherapy, n (%) | |||
Corticosteroids | 45 (61.6%) | 13 (100%) | 32 (53.3%) |
Rituximab | 19 (26.0%) | 2 (15.4%) | 17 (28.3%) |
IVIG | 8 (11%) | 4 (30.8%) | 4 (6.7%) |
Mycophenolate | 18 (24.7%) | 2 (15.4%) | 16 (26.7%) |
Cyclophosphamide | 2 (2.7%) | 1 (7.7%) | 1 (1.7%) |
Antifibrotic | 5 (6.9%) | 0 (0%) | 5 (8.3%) |
Outcome, n (%) | |||
Improved | 12 (16.4%) | 2 (15.4%) | 10 (16.7%) |
Stable | 32 (43.8%) | 32 (53.3%) | |
Progressed | 8 (11%) | 8 (13.3%) | |
Died | 21 (28.8%) | 11 (84.6%) | 10 (16.7%) |